Additional Proxy Soliciting Materials (definitive) (defa14a)
May 19 2021 - 9:28AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Information
required in proxy statement
schedule
14A information
PROXY
STATEMENT PURSUANT TO SECTION 14(A)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Filed
by the Registrant [X]
Filed
by a Party other than the Registrant [ ]
Check
the appropriate box:
[ ]
|
Preliminary Proxy Statement
|
|
|
[ ]
|
Confidential, for
Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
|
[ ]
|
Definitive Proxy Statement
|
|
|
[X]
|
Definitive Additional
Materials
|
|
|
[ ]
|
Soliciting Materials
Pursuant to Rule 14a-12
|
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
(Name
of Registrant as Specified In Its Charter)
(Name(s)
of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
[X]
|
No
fee required.
|
|
|
[ ]
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
|
(1)
|
Title
of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
|
|
|
|
|
(4)
|
Proposed
maximum aggregate value of transaction:
|
|
|
|
|
(5)
|
Total
fee paid:
|
|
|
|
[ ]
|
Fee
paid previously with preliminary materials.
|
|
|
[ ]
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its
filing.
|
|
(1)
|
Amount
Previously Paid:
|
|
|
|
|
(2)
|
Form,
Schedule or Registration Statement No.:
|
|
|
|
|
(3)
|
Filing
Party:
|
|
|
|
|
(4)
|
Date
Filed:
|
|
|
|
CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF
ANNUAL MEETING
Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) –
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage
drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it has adjourned
its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) in order to provide stockholders additional time within which
to vote on all proposals, including Proposal 4 to approve an amendment to the Company’s certificate of incorporation to increase
the Company’s authorized shares of common stock from 150,000,000 to 300,000,000.
The Company believes there is significant support
for Proposal 4. At the time of the Annual Meeting, approximately 85% of the votes cast on Proposal 4 were voted in favor of its approval.
Because Proposal 4 must be approved by a majority of the outstanding shares of common stock, however, it has not yet received a sufficient
number of votes in its favor. Because Corbus’ Board of Directors continues to believe that Proposal 4 is advisable and in the best
interests of the Company’s stockholders to consider and act upon Proposal 4, the Company adjourned the Annual Meeting.
The adjourned meeting will be held at 9:00 a.m. ET
on Thursday, June 17, 2021 at the following url: www.viewproxy.com/corbuspharma/2021/vm. The record date for the annual meeting is March
31, 2021.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage
company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s
lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative
to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated
in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its
endocannabinoid system platform.
Lenabasum is not approved for the treatment of any
indication. For more information on Corbus’ clinical programs, please visit here.
For more information, visit http://www.corbuspharma.com/,
and connect with us on Twitter, LinkedIn, and Facebook.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and
Corporate Communications
Phone: +1 (617) 415-7745
Email: ir@corbuspharma.com
Lindsey Smith, Director, Investor Relations and Corporate
Communications
Phone: +1 (617) 415-7749
Email: mediainfo@corbuspharma.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2024 to May 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From May 2023 to May 2024